



CHEMOSENSITIVITY ASSAYS

Effective Date: September 21, 2009

Review Dates: 8/09

Date Of Origin: August 12, 2009

Status: New

I. DESCRIPTION

Chemosensitivity assays are designed to predict tumor response to various chemotherapies. These assays have been proposed for use by oncologists to select chemotherapy regimens for individual patients. A variety of assays have been developed that differ in their processing and in the technique used to measure sensitivity or resistance. All involve the same four basic steps: 1) isolation of cells, 2) incubation of cells with drugs, 3) assessment of cell survival, and 4) interpretation of the result. A variety of techniques have been evaluated to assess cell survival, including the DISC (differential staining cytotoxicity) assay, the thymidine incorporation assay, fluorescence (cytoprint) assays, and the MTT (methylthiazolyl-diphenyl-tetrazolium bromide) assay.

Results are reported as either drug sensitive, drug resistant, or intermediate. Drugs identified as drug sensitive are thought to be potentially effective in chemotherapy, while drugs identified as resistant are thought to be potentially ineffective chemotherapies.

II. POLICY/CRITERIA

- A. Currently the only assay covered by Priority Health for clinical use is ChemoFx®. ChemoFx® measures both resistance and sensitivity which analyzes which chemotherapies are least likely to work for an individual patient and which are most likely to work.
- B. The use of ChemoFx® is currently only approved for ovarian, fallopian tube and primary peritoneal cancers when intended for guidance in selection of chemotherapeutic agents for either primary or recurrent cancer.

III. MEDICAL NECESSITY REVIEW

Required Not Required Not Applicable

IV. APPLICATION TO PRODUCTS

Coverage is subject to member's specific benefits. Group specific policy will supersede this policy when applicable.

- ❖ HMO/EPO: *This policy applies to insured HMO/EPO plans.*
- ❖ POS: *This policy applies to insured POS plans.*



- ❖ **PPO:** *This policy applies to insured PPO plans.*
- ❖ **ASO:** *For self-funded plans, consult individual plan documents. If there is a conflict between this policy and a self-funded plan document, the provisions of the plan document will govern.*
- ❖ **INDIVIDUAL:** *For individual policies, consult the individual insurance policy. If there is a conflict between this medical policy and the individual insurance policy document, the provisions of the individual insurance policy will govern.*
- ❖ **MEDICARE:** *Coverage is determined by the Centers for Medicare and Medicaid Services (CMS).*
- ❖ **MEDICAID:** *Coverage is determined by the Michigan Medicaid Provider Manual and the Michigan Medicaid Fee Schedule at: http://www.michigan.gov/mdch/0,1607,7-132-2945_42542_42543_42546_42551-159815--00.html.*
- ❖ **MICHILD:** *For MICHILD members, this policy will apply unless MICHILD certificate of coverage limits or extends coverage.*

IV. CODING INFORMATION

ICD-9 Diagnosis Codes:

These Diagnoses may support medical necessity

- 158.0 Malignant neoplasm of retroperitoneum
- 158.8 Malignant neoplasm of specified parts of peritoneum
- 158.9 Malignant neoplasm of peritoneum, unspecified
- 183.0 Malignant neoplasm of ovary
- 183.2 Malignant neoplasm of fallopian tube

CPT/HCPCS Codes:

- 89240 Unlisted miscellaneous pathology test
- 84999 Unlisted chemistry procedure

VI. REFERENCES

Schrag D, Garewal HS, Burstein HJ, et al.; ASCO Working Group on Chemotherapy Sensitivity and Resistance Assays. American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. *J Clin Oncol.* 2004;22(17):3631-3638

Hayes Technology Assessment: ChemoFX® Assay (Precision Therapeutics Inc.) for Prediction of Response to Chemotherapy February 26, 2009

Heinzman, J., S. Brower, et. al. (2007) "Ex vivo enrichment of malignant carcinoma cells in primary culture." *Pathology*, 39 (5), 0031-3025.

Brower, S. Fensterer, J et. al. (2007) "The ChemoFx® Assay: An *Ex Vivo* Chemo-Sensitivity and Resistance Assay for Predicting Patient Response



to Cancer Chemotherapy” Methods in Molecular Biology, Molecular Medicine and Biotechnology. J. Walker Ed.

- Gallion, H. H., W. A. Christopherson, et al. (2006) "Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay." *International Journal of Gynecological Cancer* 16 (1), 194–201. doi:10.1111/j.1525-1438.2006.00301.x.
- Peters, D., J. Freund et al. (2005). “Genome-wide transcriptional analysis of carboplatin response in chemosensitive and chemoresistant ovarian cancer cells.” *Mol Cancer Ther* 4(10): 1605-16.
- Kornblith, P., R. L. Ochs, et al. (2004). "Differential in vitro effects of chemotherapeutic agents on primary cultures of human ovarian carcinoma." *International Journal of Gynecological Cancer* **14**: 607-615.
- Marsh, J., M. Donovan, et al. (2004). "Metastatic lung disease to the central nervous system: in vitro response to chemotherapeutic agents." *Journal of Neurooncology* **66**: 81-90.
- Ochs, R. L., A. Chattopadhyay, et al. (2004). "A phenotypic cell culture assay for predicting anticancer drug responses." *Preclinica* **2**(3): 205-212.
- Ochs, R. L., D. Burholt, et al. (2004). “The ChemoFx® Assay: An Ex Vivo Cell Culture Assay for Predicting Anticancer Drug Responses.” *Methods in Molecular Medicine*, vol. 110: Chemosensitivity: Vol. 1: In Vitro Assays. R. Blumenthal. Totowa, NJ, Humana Press Inc. **110**: 155-172.
- Kornblith, P., A. Wells, et al. (2003). "Breast cancer-response rates to chemotherapeutic agents studied in vitro." *Anticancer Research* **23**: 3405-3412.
- Kornblith, P., A. Wells, et al. (2003). "In vitro responses of ovarian cancers to platinum and taxanes." *Anticancer Research* **23**: 543-548.
- Ochs, R. L., J. Fensterer, et al. (2003). "Evidence for the isolation, growth, and characterization of malignant cells in primary cultures of human tumors." *In Vitro Cellular & Developmental Biology - Animal* **39**: 63-70.
- Ness, R. B., S. R. Wisniewski, et al. (2002). "Cell viability for drug testing in ovarian cancer: in vitro kill versus clinical response." *Anticancer Research* **22**: 1145-1150.
- Kornblith, P. and D. Burholt (2001). “Chemosensitivity Testing.” *Tumors of the Pediatric Central Nervous System*. R. Keating, J. Goodrich and P. RJ. New York, Thieme.



Letwin, R. L. (2001). "Chemosensitivity Testing." *Clinical Journal of Oncology Nursing* **5**(5): 195-200.

Letwin, R. L. (2001). "Chemosensitivity Testing: Individualized Patient Therapy." *Journal of Gynecologic Oncology Nursing* **11**: 63-65.

AMA CPT Copyright Statement:

All Current Procedure Terminology (CPT) codes, descriptions, and other data are copyrighted by the American Medical Association.

This document is for informational purposes only. It is not an authorization, certification, explanation of benefits, or contract. Receipt of benefits is subject to satisfaction of all terms and conditions of coverage. Eligibility and benefit coverage are determined in accordance with the terms of the member's plan in effect as of the date services are rendered. Priority Health's medical policies are developed with the assistance of medical professionals and are based upon a review of published and unpublished information including, but not limited to, current medical literature, guidelines published by public health and health research agencies, and community medical practices in the treatment and diagnosis of disease. Because medical practice, information, and technology are constantly changing, Priority Health reserves the right to review and update its medical policies at its discretion.

Priority Health's medical policies are intended to serve as a resource to the plan. They are not intended to limit the plan's ability to interpret plan language as deemed appropriate. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment they choose to provide.

The name "Priority Health" and the term "plan" mean Priority Health, Priority Health Managed Benefits, Inc., Priority Health Insurance Company and Priority Health Government Programs, Inc.